CDNA.OQ
Latest Trade
85.43USDChange
-2.23(-2.54%)Volume
396,247Today's Range
-
88.6152 Week Range
-
99.70As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 87.66 |
|---|---|
Open | 87.69 |
Volume | 396,247 |
3M AVG Volume | 13.58 |
Today's High | 88.61 |
Today's Low | 85.25 |
52 Week High | 99.70 |
52 Week Low | 13.19 |
Shares Out (MIL) | 49.26 |
Market Cap (MIL) | 4,317.89 |
Forward P/E | 547.88 |
Dividend (Yield %) | -- |
Caredx Says Public Offering Of 1.92 mln Common Shares Priced At $91 per Share
CareDx Announces Proposed Public Offering Of Common Stock
Caredx Sees Q4 2020 Revenue $58.4 Million To $58.6 Million
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Industry
Healthcare Facilities
Contact Info
1 Tower Place, 9Th Floor
SOUTH SAN FRANCISCO, CA
94080
United States
+1.415.2872300
https://www.caredx.com/Executive Leadership
Peter Maag
Executive Chairman of the Board of Directors
Reginald Seeto
President, Chief Executive Officer, Director
Marcel Konrad
Interim Chief Financial Officer
Sasha King
Chief Marketing Officer
Michael D. Goldberg
Lead Independent Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 25.49 |
Price To Book (MRQ) | 16.03 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -9.86 |
Return on Equity (TTM) | -8.02 |
* NEW KIDNEY360 PUBLICATION HIGHLIGHTS CAREDX’S ALLOSURE IS DIFFERENTIATED AS THE DD-CFDNA TEST OF CHOICE
* CAREDX FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO $100 MILLION COMMON STOCK OFFERING - SEC FILING Source : (https://bit.ly/37nRhjC) Further company coverage:
* CAREDX'S ALLOSEQ TX 17 AWARDED CE MARK APPROVAL Source text for Eikon: Further company coverage:
* CAREDX AND VERACYTE ANNOUNCE EXCLUSIVE PARTNERSHIP FOR TRANSPLANT REJECTION TESTING ON NCOUNTER SYSTEM
* CAREDX REPORTS PRELIMINARY FIRST QUARTER 2020 REVENUE AND PROVIDES BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC
* Q4 REVENUE $35.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $35.8 MILLION
* CAREDX - COURT RECOMMENDED DENIAL OF NATERA INC.'S & EUROFINS VIRACOR INC.'S MOTIONS TO DISMISS CAREDX'S PATENT INFRINGEMENT COMPLAINTS AGAINST THEM
A patent infringement lawsuit by Stanford University and licensee CareDx Inc against genetic testing company Natera Inc survived a motion to dismiss on Tuesday in U.S. District Court in Delaware.
Medical diagnostics company CareDx Inc on Wednesday escalated a legal battle with rival Natera Inc over kidney transplant technology, adding false advertising claims in a new lawsuit to what began as a patent dispute.
* FOR FULL YEAR 2018, CAREDX EXPECTS REVENUE TO BE IN RANGE OF $64 MILLION TO $66 MILLION Source text for Eikon: Further company coverage:
* CAREDX INC - ON MAY 4, 2018, CO ENTERED INTO A LICENSE AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA, INC - SEC FILING
* CAREDX SAYS ON APRIL 17 ENTERED INTO A CREDIT AGREEMENT AND GUARANTY - SEC FILING
* ANNOUNCED LAUNCH OF HEARTCARE, A COMPREHENSIVE REJECTION SURVEILLANCE SOLUTION FOR HEART TRANSPLANT RECIPIENTS Source text for Eikon: Further company coverage:
* FY2018 REVENUE VIEW $61.5 MILLION -- THOMSON REUTERS I/B/E/S
* CAREDX - ENTERED BINDING COMMITMENT WITH PERCEPTIVE ADVISORS FOR A TERM LOAN OF BETWEEN $15 MILLION AND $35 MILLION
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.